Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats

R Miatello1, N Risler, C Castro

  • 1Dept. of Pathology, School of Medicine, National University of Cuyo, Av. Libertador 80, Centro Universitario 5500, Mendoza, Argentina. rmiatell@fcm.uncu.edu.ar

Insights

Losartan treatment improved endothelial dysfunction and smooth muscle cell proliferation in rats with Syndrome X. This suggests the renin-angiotensin system plays a key role in this condition.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Pharmacology

Background:

  • Syndrome X, characterized by hyperinsulinemia, insulin resistance, hypertriglyceridemia, and hypertension, is linked to endothelial dysfunction.
  • The role of the renin-angiotensin system (RAS) in Syndrome X remains unclear.

Purpose of the Study:

  • To investigate the effect of losartan, an angiotensin AT1 receptor antagonist, on endothelial nitric oxide synthase (eNOS) activity and smooth muscle cell (SMC) proliferation in a rat model of Syndrome X.
  • To elucidate the involvement of the RAS in the pathophysiology of Syndrome X.

Main Methods:

  • Fructose-fed rats (FFR) were used as a model for Syndrome X.
  • Rats received chronic losartan (L) administration.
  • eNOS activity was measured in aortic endothelium and cardiac tissue.
  • SMC proliferation was assessed using 3H-thymidine incorporation and cell counting.

Main Results:

  • FFR exhibited increased SMC proliferation and decreased aortic and cardiac eNOS activity compared to controls.
  • Losartan treatment reduced systolic blood pressure and cardiac hypertrophy.
  • Losartan administration restored eNOS activity and abolished increased SMC proliferation.

Conclusions:

  • Endothelial dysfunction and altered SMC proliferation are key components of Syndrome X.
  • AT1 receptor blockade with losartan effectively reverses these pathological changes.
  • The RAS plays a significant role in Syndrome X, potentially involving AT2 receptors and kinins.